Leaders in Pharmaceutical Business Intelligence (LPBI) Group

PROGRAM ANNOUNCEMENT

Conference Program is available at

http://www.sachsforum.com/newyork14/

Event’s agenda available at:
http://www.sachsforum.com/newyork14/newyork14-agenda.html

Wednesday, 19th March 2014
Registration and coffee begins – 08.00
Program begins – 08.15
Networking reception will take place at 18.00 – 20.00

Once you arrive at 7 World Trade Center (250 Greenwich St, New York, NY10007, USA).
Please use the D Elevator Bank to the 40th floor where Sachs Team will welcome you at the registration desk.

For urgent issues, please contact:
Tomas@sachsforum.com (cell number +44 77 043 158 71)
Or Mina@sachsforum.com (cell number +44 74 636 695 04) Cells available from 15th March.

Announcement

LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE will cover the event for the Scientific Media

Dr. Lev-Ari will be in attendance on 3/19/2014 at 

The New York Academy of Sciences.

Editorials of event coverage via our 

Open Access Scientific Journal

http://pharmaceuticalintelligence.com

Date             Views to Date      # of articles      “NIH Clicks”  “Nature Clicks”

3/05/2014      338,958                 1,717                 1,830                   965

• 369 Articles on Cancer
• 74 articles on Imaging-based Cancer Patient Management

http://pharmaceuticalintelligence.com/?s=Cancer+

• Cancer e-Book

Series C: e-Books on Cancer & Oncology

VOLUME ONE 

Cancer Biology and Genomics for Disease Diagnosis

2014

Stephen J. Williams, PhD, Senior Editor

sjwilliamspa@comcast.net

Tilda Barliya, PhD, Editor

tildabarliya@gmail.com

Ritu Saxena, PhD, Editor

ritu.uab@gmail.com

http://pharmaceuticalintelligence.com/biomed-e-books/series-c-e-books-on-cancer-oncology/cancer-biology-and-genomics-for-disease-diagnosis/

SIX SOURCES of INVESTMENT for BioMed INVENTIONS

Curator: Aviva Lev-Ari, PhD, RN

Investing and inventing: Is the Tango of Mars and Venus Still on

MEDIA COVERAGE

The Event will be broadcasted via our distributions channels on the Internet and all Search Engines featuring WordPress.com

• Scientific Journal

http://pharmaceuticalintelligence.com

http://pharmaceuticalintelligence.com/2014/03/05/milestone-for-our-venture-we-celebrate-our-top-authors-by-number-of-articles-in-the-journal-to-date-1000-301-58-49-46-43-40-28-20/

• Facebook HomePage of LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE

http://www.facebook.com/LeadersInPharmaceuticalBusinessIntelligence

• On Twitter.com  @pharma_BI

http://twitter.com/pharma_BI

• 53 BioMed Groups on LinkedIn.com

http://www.linkedin.com/in/avivalevari

• Dr. Lev-Ari’s BioMed Group launched by and managed by on LinkedIn.com – LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE

http://www.linkedin.com/groups?gid=4346921&trk=hb_side_g

2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum Promoting Public & Private Sector Collaboration & Investment in Drug Development 19th March 2014 • New York Academy of Sciences • USA

http://www.sachsforum.com/newyork14/

 

The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment. We expect around 200 delegates and there is an online meeting system and meeting facilities to make the event transactional. There will also be a track of about 30 presentations by listed and private biotechnology companies seeking licensing/investment.

The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum will cover the following topics in the program:

• Advances in Translational Research
• Strategies for Small Molecule and Biologicals Drug Development
• Deal Making
• Public & Private Partnerships
• Diagnostics
• Immunotherapies and Cancer Vaccines
• Case Study

Confirmed Speakers & Chairs include:
Anne Altmeyer, Executive Director Business Development & Licensing, Novartis Pharmaceuticals
Ariel Jasie, Executive Director of Business Development, Celgene
Beth Jacobs, Managing Partner, Excellentia Global Partners
Boris Peaker, Executive Director, Biotechnology Equity Research, Oppenheimer & Co. Inc.
Carole Nuechterlein, Head Roche Venture Fund, F.Hoffmann-La Roche AG Roche Venture Fund
Dan Snyder, President and COO, MolecularMD
Daryl Mitteldorf, Executive Director, Global Prostate Cancer Alliance
Dennis Purcell, Senior Managing Partner, Aisling Capital
Doug Plessinger, Vice President of Clinical and Medical Affairs, Argos Therapeutics, Inc.
Elizabeth Bachert, Senior Director Worldwide Business Development, Pfizer
Esteban Pombo-Villar, COO, Oxford BioTherapeutics AG
Florian Schodel, CEO, Philimmune LLC
Frederick Cope, President and CSO, Navidea Biopharmaceuticals
Guillaume Vignon, Director of Global BD Oncology, Merck Serono SA
Harren Jhoti, President, Astex Pharmaceuticals Inc.
Harry Glorikan, Managing Director, Precision for Medicine
James Mulé, Executive Vice President and Associate Center Director for Translational Research,
H Lee Moffit Cancer Center
Keith Knutson, Program Director and Principal Investigator of the Cancer Vaccines and immune Therapies Program, Vaccine and Gene Therapy Institute of Florida
Kevin DeGeeter, Analyst, Ladenburg Thalmann & Co, Inc.
Klaus Urbahns, Head, Discovery Technologies, Merck Serono
Kristina Khodova, Project Manager, Oncology, Skolkovo Foundation
Lorenza Castellon, Business Development Consultant, Suda Ltd.
Louis DeGennaro, Executive VP, CMO, The Leukemia and Lymphoma Society
Louise Perkins, Chief Science Officer, Melanoma Research Alliance
Mara Goldstein, Managing Director, Senior Healthcare Analyst, Cantor Fitzgerald
Michael Goldberg, Managing Partner, Montaur Capital
Nathan Tinker, Executive Director, NewYorkBIO
Nicholas Dracopoli, Vice President and Head of Oncology, Janssen Research & Development
Peter Hoang, Managing Director, Office of Innovations, Technology Based Ventures, The University of Texas MD Anderson Cancer Center
Philip Gotwals, Executive Director, Oncology Research Collaborations, Novartis Institutes for BioMedical Research
Robert Petit, CSO, Advaxis Inc.
Stephen Brozak, Managing Partner and President, WBB Securities, LLC
Steven Tregay, CEO, Forma Therapeutics
Steven W. Young, President, Addario lung Cancer Medical Institute
Stuart Barich, Managing Director, Healthcare Investment Banking, Oppenheimer & Company
Tariq Kassum MD, Vice President, Business Development and Strategy, Millennium Pharmaceuticals
TBC, Cardinal Health
TBC, UCSD
Timothy Herpin, Vice President, Head of Transactions (UK), Business Development, AstraZeneca
Vikas Sharma, Director, Business Development, Rexahn Pharmaceuticals, Inc.
Walter Capone, President, The Multiple Myeloma Research Foundation

View the full list of 2013 Forum Speakers & Chairs >>

Presenting Opportunities for Biotech, Pharmaceutical companies  and Patient Advocacy Groups

Presenting at the forum offers excellent opportunities to showcase activities and highlight investment and partnership opportunities. Biotech companies will be able to communicate investment and licensing opportunities. These are for both public and private companies. The audience is comprised of financial and industry investors. These are streamed 15 minute presentations. The patient advocacy presentations are 30 minutes.

Sachs forums are recognised as the leading international stage for those interested in investing in the biotech and life science industry and are highly transactional. They draw together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharmas. The Boston forum provides the additional interaction with the academic/scientific and patient advocacy communities.

Sponsorship and Exhibition

Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market.

Raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.

To learn more about presenting, exhibition or sponsorship opportunities, please contact
Mina Orda + 44 (0)203 463 4890 or by email: Mina Orda.

	Register Now Register To Exhibit Register To Present OVERVIEW Speakers Presenting Companies Attendees Program Sponsors / Supporters Venue Accommodation
	Companies Who Presented at the 2013 Forum Included: Aileron Therapeutics, Inc. AnaptysBio, Inc Argos Therpeutics, Inc Atossa Genetics BioCancell Ltd. BioLineRx Ltd. Cellectis CENTROSE Churchill Pharmaceuticals Constellation Pharmaceuticals CureVac GmbH Dicerna Pharmaceuticals Etubics Corporation Genisphere immatics biotechnologies GmbH ImmunoGen, Inc Life Science Nation MacroGenics, Inc Melanovus Oncology MiNA Therapeutics MolecularMD Oncolix, Inc. OncoSec Medical Incorporated Oxford BioTherapeutics RAMOT at Tel Aviv University Rescue Therapeutics, Inc. Sialix, Inc. Sorrento Therapeutics to-BBB technologies BV TVAX Biomedical, Inc. The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment. We expect around 200 delegates and there is an online meeting system and meeting facilities to make the event transactional. There will also be a track of about 30 presentations by listed and private biotechnology companies seeking licensing/investment.The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum will cover the following topics in the program: Advances in Translational Research Strategies for Small Molecule and Biologicals Drug Development Deal Making Public & Private Partnerships Confirmed Speakers & Chairs include: The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum will cover the following topics in the program: Advances in Translational Research Strategies for Small Molecule and Biologicals Drug Development Deal Making Public & Private Partnerships Diagnostics Immunotherapies and Cancer Vaccines Confirmed Speakers & Chairs include: Anne Altmeyer, Executive Director Business Development & Licensing, Novartis Pharmaceuticals Ariel Jasie, Executive Director of Business Development, Celgene Beth Jacobs, Managing Partner, Excellentia Global Partners Boris Peaker, Executive Director, Biotechnology Equity Research, Oppenheimer & Co. Inc. Carole Nuechterlein, Head Roche Venture Fund, F.Hoffmann-La Roche AG Roche Venture Fund Daryl Mitteldorf, Executive Director, Global Prostate Cancer Alliance Dennis Purcell, Senior Managing Partner, Aisling Capital Doug Plessinger, Vice President of Clinical and Medical Affairs, Argos Therapeutics, Inc. Elizabeth Bachert, Senior Director Worldwide Business Development, Pfizer Esteban Pombo-Villar, COO, Oxford BioTherapeutics AG Florian Schodel, CEO, Philimmune LLC Guillaume Vignon, Director of Global BD Oncology, Merck Serono SA Harren Jhoti, President, Astex Pharmaceuticals Inc. Harry Glorikan, Managing Director, Precision for Medicine James Mulé, Executive Vice President and Associate Center Director for Translational Research, H Lee Moffit Cancer Center Keith Knutson, Program Director and Principal Investigator of the Cancer Vaccines and immune Therapies Program, Vaccine and Gene Therapy Institute of Florida Klaus Urbahns, Head, Discovery Technologies, Merck Serono Kristina Khodova, Project Manager, Oncology, Skolkovo Foundation Lorenza Castellon, Business Development Consultant, Suda Ltd. Louis DeGennaro, Executive VP, CMO, The Leukemia and Lymphoma Society Louise Perkins, Chief Science Officer, Melanoma Research Alliance Mara Goldstein, Managing Director, Senior Healthcare Analyst, Cantor Fitzgerald Nathan Tinker, Executive Director, NewYorkBIO Nicholas Dracopoli, Vice President and Head of Oncology, Janssen Research & Development Peter Hoang, Managing Director, Office of Innovations, Technology Based Ventures, The University of Texas MD Anderson Cancer Center Philip Gotwals, Executive Director, Oncology Research Collaborations, Novartis Institutes for BioMedical Research Robert Petit, CSO, Advaxis Inc. Steven Tregay, CEO, Forma Therapeutics Steven W. Young, President, Addario lung Cancer Medical Institute Stuart Barich, Managing Director, Healthcare Investment Banking, Oppenheimer & Company Tariq Kassum MD, Vice President, Business Development and Strategy, Millennium Pharmaceuticals Timothy Herpin, Vice President, Head of Transactions (UK), Business Development, AstraZeneca Walter Capone, President, The Multiple Myeloma Research Foundation _______ View the full list of 2013 Forum Speakers & Chairs >> Presenting Opportunities for Biotech, Pharmaceutical companies  and Patient Advocacy Groups Presenting at the forum offers excellent opportunities to showcase activities and highlight investment and partnership opportunities. Biotech companies will be able to communicate investment and licensing opportunities. These are for both public and private companies. The audience is comprised of financial and industry investors. These are streamed 15 minute presentations. The patient advocacy presentations are 30 minutes. Sachs forums are recognised as the leading international stage for those interested in investing in the biotech and life science industry and are highly transactional. They draw together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharmas. The Boston forum provides the additional interaction with the academic/scientific and patient advocacy communities. Sponsorship and Exhibition Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market. Raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events. To learn more about presenting, exhibition or sponsorship opportunities, please contact Mina Orda + 44 (0)203 463 4890 or by email: Mina Orda. SOURCE http://www.sachsforum.com/newyork14/index.html From: Mina@sachsforum.com To: AvivaLev-Ari@alum.berkeley.edu Sent: Mon Dec 16 12:01:21 UTC 2013 From: Tomas Andrulionis <Tomas@sachsforum.com> Date: Tue, 10 Dec 2013 16:13:53 +0000 To: “avivalev-ari@alum.berkeley.edu” <avivalev-ari@alum.berkeley.edu> Conversation: Complimentary Invitation for the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum, 19th March 2014, New York Academy of Sciences